Opinion|Videos|July 17, 2024
Exploring Data Outcomes From the SUNLIGHT Trial
Leading colorectal cancer specialists analyze the SUNLIGHT trial results, focusing on age-related efficacy data and its implications for treatment strategies.
Advertisement
Episodes in this series
- Briefly summarize the SUNLIGHT trial, evaluating TAS-102 ± bevacizumab in patients with mCRC (
Prager, et al. NEJM, 2023 )- Dr Fakih: How does age impact efficacy and safety outcomes from the SUNLIGHT trial in mCRC? (
Taieb J, et al. ASCO GI 2024. Abstract 111 ) - Dr Benson: What is the impact of colorectal liver metastases (CRLM) in patients with mCRC treated with TAS-102 ± bevacizumab? (
Tabernero J, et al. ASCO 2024. Abstract 3584. )
- Dr Fakih: How does age impact efficacy and safety outcomes from the SUNLIGHT trial in mCRC? (
Advertisement
Related to this article
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
The success of RASolute 302 positions daraxonrasib to transform RAS-mutant pancreatic cancer care and accelerate pan-RAS development across tumors.
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Longer duration of adjuvant FOLFOX and atezolizumab was associated with improved DFS in a retrospective analysis of the ATOMIC trial.
Adagrasib in combination with cetuximab did not significantly improve OS or PFS in KRAS G12C–mutated metastatic colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
Rocbrutinib Displays Durable Activity in Covalent BTK Inhibitor–Pretreated R/R MCL
4
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
5